• NEBANNER

Featured

  • Manufacturer for Sai Surface Coating Technologies - (2-butyl-5-nitro-1-benzofuran-3-yl)-[4-[3-(dibutylamino)propoxy]phenyl]methanone – JIN DUN

    Manufacturer for Sai Surface Coating Technologies - (2-butyl-5-nitro-1-benzofuran-3-yl)-[4-[3-(dibutylamino)propoxy]phenyl]methanone – JIN DUN

    (2-butyl-5-nitro-1-benzofuran-3-yl)-[4-[3-(dibutylamino)propoxy]phenyl]methanone is used as the intermediate of Dronedarone . Dronedarone is an antiarrhythmic drug. It is suitable for patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), reducing the risk of hospitalization, patients with recent AF / AFL attacks and cardiovascular risk factors, and patients with sinus rhythm or cardioversion. About the pharmacological action, pharmacokinetics, drug interacti...
  • Factory made hot-sale Inhibitor Ppm - 7-ethylcamptothecin – JIN DUN

    Factory made hot-sale Inhibitor Ppm - 7-ethylcamptothecin – JIN DUN

    7-ethylcamptothecin is used as the intermediate of Irinotecan. Irinotecan antitumor drug. It is an inhibitor of DNA synthesis. It is a semi synthetic derivative of camptothecin; Used for preparing irinotecan hydrochloride and irinotecan hydrochloride trihydrate; Large scale clinical trials have shown that irinotecan hydrochloride has obvious inhibitory effects on a variety of tumors, such as colon cancer, small cell lung cancer, rectal cancer and leukemia, and is still effective in fluorourac...
  • Factory best selling Groundwater Treatment Process - Guanosine – JIN DUN

    Factory best selling Groundwater Treatment Process - Guanosine – JIN DUN

    Guanosine is used as the intermediate of Valaciclovir. Valacyclovir is a guanine analogue antiviral drug. It is used in the clinical treatment of herpes simplex and herpes zoster infection in sexually transmitted diseases. This product is the precursor of acyclovir. It is absorbed rapidly after oral administration and quickly transformed into acyclovir in the body. Its antiviral effect is played by acyclovir. After acyclovir enters herpes infected cells, it competes with deoxynucleoside for v...
  • 8 Year Exporter Whole House Water Treatment Systems - Ethylmethyl-carbamic chloride – JIN DUN

    8 Year Exporter Whole House Water Treatment Systems - Ethylmethyl-carbamic chloride – JIN DUN

    Ethylmethyl-carbamic chloride is used as the intermediate of Rivastigmine tartrate . Rivastigmine tartrate is rivastigmine Alzheimer’s disease drugs, rivastigmine is physostigmine derivative by Novartis for the first time successfully developed the trade name Exelon (exelon), a molecule with there carbamate structure, is a kind of amino acid of selective cerebral cholinesterase inhibitor, can also inhibit the acetylcholinesterase and butyrylcholinesterase, cholinergic neurons by delayin...
  • Best Price on Iron Removal Filter - FondaparinSodiuM;Fondaparinux SodiuM Identification;Fondaparinux sodium N-4; – JIN DUN

    Best Price on Iron Removal Filter - FondaparinSodiuM;Fondaparinux SodiuM Identification;Fondaparinux sodium N-4; – JIN DUN

    Fondaparinux Biological Activity Describe Fondaparinux sodium is an antithrombin-dependent factor Xa inhibitor。 Related Categories signal path >> Metabolic enzymes/proteases >> Factor Xa Research areas >> Cardiovascular diseases Target Factor Xa[1] In vitro studies Fondaparinux sodium is the first new anticoagulant that selectively targets factor Xa. For Fondaparinux, the IC50 value (anti-Xa IU/ml) of activated monocytes (ac-M) is 0.59±0.05, and monocyte-derived pa...
  • Professional China Antipsychotic Tablets - 3′-Amino-2′-hydroxy-[1,1'-bipheny]-3-carboxylic acid – JIN DUN

    Professional China Antipsychotic Tablets - 3′-Amino-2′-hydroxy-[1,1'-bipheny]-3-carboxylic acid – JIN DUN

    3′-Amino-2′-hydroxy-[1,1'-bipheny]-3-carboxylic acid is used as the intermediate of Eltrombopag . Eltrombopag, developed by GlaxoSmithKline (GSK) in the UK and later jointly developed with Novartis in Switzerland, is the first and only approved small molecule non peptide TPO receptor agonist in the world. Eltrombopag was approved by the US FDA in 2008 for the treatment of idiopathic thrombocytopenic purpura (ITP), and in 2014 for the treatment of severe aplastic anemia (AA). It is...
  • Top Suppliers Bleaching Well Water - 2-deoxy-2,2-difluoro-3,5-o-dibenzoylribose mesylate – JIN DUN

    Top Suppliers Bleaching Well Water - 2-deoxy-2,2-difluoro-3,5-o-dibenzoylribose mesylate – JIN DUN

    2-deoxy-2,2-difluoro-3,5-o-dibenzoylribose mesylate is used as the intermediate of Gemcitabine. Gemcitabine is a pyrimidine nucleotide analogue, which belongs to anti metabolic anticancer drugs. It can prevent the progress of DNA synthesis in a certain period, that is, S-phase. It has the characteristics of wide anticancer spectrum, unique mechanism of action, low toxicity, no cross resistance with other chemotherapeutic drugs and no superposition of toxicity. Today, gemcitabine has been appr...
  • Discount Price Silicon/Fluorine Uv Resin - ( R )-2,3-o-isopropylidene-glyceraldehyde – JIN DUN

    Discount Price Silicon/Fluorine Uv Resin - ( R )-2,3-o-isopropylidene-glyceraldehyde – JIN DUN

    ( R )-2,3-o-isopropylidene-glyceraldehyde is used as the intermediate of Gemcitabine. Gemcitabine is a pyrimidine nucleotide analogue, which belongs to anti metabolic anticancer drugs. It can prevent the progress of DNA synthesis in a certain period, that is, S-phase. It has the characteristics of wide anticancer spectrum, unique mechanism of action, low toxicity, no cross resistance with other chemotherapeutic drugs and no superposition of toxicity. Today, gemcitabine has been approved for u...
  • Fixed Competitive Price Sterilization Of Water - 3′-Amino-2′-hydroxy-[1,1'-bipheny]-3-carboxylic acid – JIN DUN

    Fixed Competitive Price Sterilization Of Water - 3′-Amino-2′-hydroxy-[1,1'-bipheny]-3-carboxylic acid – JIN DUN

    3′-Amino-2′-hydroxy-[1,1'-bipheny]-3-carboxylic acid is used as the intermediate of Eltrombopag . Eltrombopag, developed by GlaxoSmithKline (GSK) in the UK and later jointly developed with Novartis in Switzerland, is the first and only approved small molecule non peptide TPO receptor agonist in the world. Eltrombopag was approved by the US FDA in 2008 for the treatment of idiopathic thrombocytopenic purpura (ITP), and in 2014 for the treatment of severe aplastic anemia (AA). It is...
  • Europe style for Wastewater Solutions - 2-((6-chloro-3-Methyl-2,4-dioxo-3,4-dihydropyriMidin-1(2H)-yl)Methyl)-4-fluorobenzonitrile – JIN DUN

    Europe style for Wastewater Solutions - 2-((6-chloro-3-Methyl-2,4-dioxo-3,4-dihydropyriMidin-1(2H)-yl)Methyl)-4-fluorobenzonitrile – JIN DUN

    2-((6-chloro-3-Methyl-2,4-dioxo-3,4-dihydropyriMidin-1(2H)-yl)Methyl)-4-fluorobenzonitrile is used as the intermediate of Trelagliptin succinate . Trogliptin succinate is a dipeptidyl peptidase Ⅳ (DPP – Ⅳ) inhibitor developed by Takeda (Takeda Pharmaceutical Co., Ltd.) in Japan. It can selectively and continuously inhibit DPP – Ⅳ and control blood glucose level. Clinical trials show that the drug has good safety and effectiveness. Once a week can effectively control the blood gluc...
  • High Quality Ultraviolet Water Treatment - 8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3 – JIN DUN

    High Quality Ultraviolet Water Treatment - 8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3 – JIN DUN

    Use: Intermediate for Linagliptin. Use:Intermediate for Linagliptin Executive standard: enterprise standard Assay:98-102% Exterior:White to light yellow powder Package: 25kg/drum To analyze the existing linagliptin and its key intermediate 8-bromo-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl -2-quinazolinyl)methyl)-1H-purine-2,6-dione (11) synthesis method, find a synthetic route suitable for industrial production. Method: summarize the different synthetic routes. Results and conclusio...
  • Chinese wholesale Hypochlorous Acid Water Treatment - 2′-Methoxy-3′-nitro-biphenyl-3-carboxylic acid – JIN DUN

    Chinese wholesale Hypochlorous Acid Water Treatment - 2′-Methoxy-3′-nitro-biphenyl-3-carboxylic acid – JIN DUN

    2′-Methoxy-3′-nitro-biphenyl-3-carboxylic acid is used as the intermediate of Eltrombopag . Eltrombopag, developed by GlaxoSmithKline (GSK) in the UK and later jointly developed with Novartis in Switzerland, is the first and only approved small molecule non peptide TPO receptor agonist in the world. Eltrombopag was approved by the US FDA in 2008 for the treatment of idiopathic thrombocytopenic purpura (ITP), and in 2014 for the treatment of severe aplastic anemia (AA). It is also ...